Skip to main content
    R

    Revelation Biosciences Inc (REVB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.76
    +0.04 (+5.81%)

    Market Cap: $2.87M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    61%(14/23)
    Avg Surprise
    +6.10%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.88
    Range$-0.94 - $-0.82
    2 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-0.81-9.3%
    60d ago$-0.81-9.3%
    30d ago$-0.81-9.3%
    7d ago$-0.81-9.3%
    Current$-0.88
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-2.33
    Range$-2.34 - $-2.31
    2 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-2.33---
    Sep 26EST
    		-$-0.88---
    Jun 26
    Reported Aug 7
    		$-0.87$-0.83-4.82%Miss+87.6%
    Mar 26
    Reported May 7
    		$-2.71$-1.15-135.65%Miss+89.3%
    Dec 25
    Reported Feb 26
    		$-1.65$-1.41-17.02%Miss+66.9%
    Sep 25
    Reported Nov 6
    		$-7.08$-5.34-32.58%Miss+95.6%
    Jun 25
    Reported Aug 7
    		$-7.01$-4.46-57.17%Miss+99.3%
    Mar 25
    Reported May 8
    		$-25.32N/A+69.33%Beat+94.6%
    Dec 24
    Reported Mar 6
    		$-4.98N/A+51.74%Beat+40.2%
    Sep 24
    Reported Nov 8
    		$-161.28N/A+70.42%Beat+93.5%
    Jun 24
    Reported Aug 9
    		$-984.96$-346.56-184.21%Miss+46.9%
    Mar 24
    Reported May 10
    		$-472.32N/A+54.32%Beat-17029.0%
    Dec 23
    Reported Mar 22
    		$-8.33$-13.77+39.51%Beat+99.9%
    Sep 23
    Reported Nov 9
    		$-2488.78$-1929.60-28.98%Miss+79.4%
    Jun 23
    Reported Aug 11
    		$-1854.72$-1872.00+0.92%Beat+92.3%
    Mar 23
    Reported May 22
    		$2.79$-0.65+529.23%Beat+100.0%
    Dec 22
    Reported Mar 30
    		$-12904.14$-10080.01-28.02%Miss+56.3%
    Sep 22
    Reported Nov 10
    		$-12096.03$-18144.04+33.33%Beat-2879907.1%
    Jun 22
    Reported Aug 15
    		$-24192.05$-28224.06+14.29%Beat-3313879.5%
    Mar 22
    Reported Apr 15
    		$-94752.20$-28224.06-235.71%Beat-59220025.0%
    Dec 21
    Reported Dec 31
    		$-29509.83N/AN/ABeat+17.9%
    Sep 21
    Reported Oct 29
    		$-0.42N/AN/ABeat-
    Jun 21
    Reported Aug 23
    		$-0.73N/AN/ABeat-212.3%
    Mar 21
    Reported Jun 22
    		$-0.16N/AN/ABeat-123.2%
    Dec 20
    Reported Mar 31
    		$-35941.58N/AN/ABeat-5529573.9%
    Sep 20
    Reported Nov 16
    		$0.00$0.00N/ABeat-100.0%
    Dec 19
    Reported Jan 28
    		$0.65$0.00N/ABeat+10.2%
    Sep 19
    Reported Oct 24
    		$0.69$0.68+1.47%Beat+6.2%
    Jun 19
    Reported Jul 24
    		$0.65$0.64+1.56%Beat-
    Mar 19
    Reported Apr 29
    		$0.62$0.61+1.64%Beat-
    Dec 18
    Reported Jan 29
    		$0.59$0.61-3.28%Miss-
    Sep 18
    Reported Nov 9
    		$0.65$0.65+0.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.06EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-154.80%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio6.21xQuick Ratio6.21x
    Trading Statistics
    Beta-0.06Avg Volume39.02K
    52-Week High$5.5252-Week Low$0.71

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.76
    SMA 20$0.82
    SMA 50$0.95
    SMA 200$1.33
    EMA 10$0.77
    EMA 20$0.82
    EMA 50$0.91
    EMA 200$2.86

    MACD

    Line: -0.06Signal: -0.06Hist: -0.00

    ADX

    ADX: 36.3+DI: 10.5-DI: 24.4

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down96.0
    PSAR$0.78

    Bollinger Bands

    Upper Band$0.98
    Lower Band$0.67
    %B Position3869%(Upper)
    Band Width0.30

    RSI (14-Day)

    Neutral
    38.9

    Momentum Oscillators

    Stoch %K11.4
    Stoch %D7.2
    Williams %R-70.6
    ROC (10d)-4.9%
    Momentum-0.04
    CCI (20d)-78.3
    MFI (14d)30.4

    Volatility Measures

    ATR (14d)$0.06(7.5%)
    StdDev (20d)0.08
    Hist Vol69.7%(High)

    Volume Flow

    VWAP$0.76
    OBV-55.2M
    AD Line11.1B
    CMF (20d)-0.526

    Volume Metrics

    Avg Vol (20d)40.7K
    Vol Ratio0.5x
    VWMA (20d)$0.82

    Pivot Points

    R3$0.81
    R2$0.79
    R1$0.75
    Pivot Point$0.73
    S1$0.70
    S2$0.68
    S3$0.64

    Advanced Oscillators

    TSI-31.12
    Ultimate Osc33.9
    KST-217.02

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$26,964$0$0$0$37,574$0
    Cost of Revenue$0$0$5,852$0$0$0$13,482$0$0$0$18,787$0
    Gross Profit$0$0$-5,852$0$0$0$13,482$0$0$0$18,787$0
    Operating Expenses$3.66M$3.09M$2.57M$1.94M$2.46M$2.09M$1.75M$1.80M$2.52M$1.90M$2.33M$2.78M
    R&D$1.92M$1.38M$964,190$922,857$1.32M$858,830$605,504$830,981$1.39M$717,582$1.06M$1.65M
    SG&A$1.74M$1.72M$1.61M$1.02M$1.14M$1.24M$1.15M$965,705$1.13M$1.18M$1.27M$1.13M
    Operating Income$-3,662,241$-3,092,500$-2,571,587$-1,943,011$-2,461,229$-2,094,987$-1,753,888$-1,796,686$-2,522,397$-1,902,138$-2,325,890$-2,777,897
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$444,879$5.87M$779,295$0$0
    Income Before Tax$-3,323,384$-3,009,051$-2,511,006$-1,907,176$-2,444,382$-2,051,085$-1,725,719$-2,241,565$-8,389,819$-2,681,433$-2,202,903$-2,628,376
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-3,323,384$-3,009,051$-2,511,006$-1,907,176$-2,444,382$-2,051,085$-1,725,719$-2,241,565$-8,389,819$-2,681,433$-2,202,903$-2,628,376
    EBITDA$-3,315,071$-3,001,848$-2,505,154$-1,900,411$-2,437,162$-2,043,864$-1,718,498$-2,234,345$-8,382,599$-2,675,171$-2,196,641$-2,622,114
    EBIT$-3,323,384$-3,009,051$-2,511,006$-1,907,176$-2,444,382$-2,051,085$-1,725,719$-2,241,565$-8,389,819$-2,681,433$-2,202,903$-2,628,376
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about REVB

    News

    Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20

    Revelation Biosciences, Inc. (Nasdaq: REVB) announced a 1-for-7 reverse stock split of its common stock, effective October 20...

    citybiz•10/16/26•Somewhat-Bearish

    Revelation Biosciences announces 1-for-7 reverse stock split

    Revelation Biosciences (REVB) announced a 1-for-7 reverse stock split effective October 20th to increase its per-share trading price and meet Nasdaq's listing requirements. This adjustment will proportionately affect...

    TradingView•10/16/26•Neutral

    Price to book forward of Revelation Biosciences, Inc. – NASDAQ:REVB

    This page displays the "Price to book forward" metric for Revelation Biosciences, Inc. (NASDAQ: REVB). It is a financial data point provided by TradingView...

    TradingView•8/22/26•Neutral

    Price to earnings forward of Revelation Biosciences, Inc. – NASDAQ:REVB

    This article provides financial data for Revelation Biosciences, Inc. (NASDAQ: REVB), specifically focusing on its forward price-to-earnings ratio. The content is primarily a data page from TradingView...

    TradingView•8/20/26•Neutral

    Revelation Biosciences grants restricted stock awards to CEO and CFO

    Revelation Biosciences, Inc. (NASDAQ:REVB) has granted restricted stock awards to CEO James Rolke and CFO Chester S. Zygmont, III, under its 2021 Equity Incentive Plan. These awards...

    Investing.com•8/20/26•Neutral

    REVB Valuation and Fair Value

    P/E
    -0.1x
    Forward P/E
    0.9x
    P/B
    0.3x
    See GNG's fair value

    REVB Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -154.8%

    REVB Competitors

    CompanyTicker
    Bioatla IncBCAB
    Painreform LtdPRFX
    Onconetix IncONCO
    HCW Biologics IncHCWB
    Ridgetech, Inc.RDGT
    INVO Fertility, Inc.IVF
    XORTX Therapeutics IncXRTX
    VivoSim Labs, Inc.VIVS

    Sector: Healthcare

    REVB Bull Case vs Bear Case

    Bear case

    • REVB beat EPS estimates in 37.5% of its last 8 reported quarters.

    REVB Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -7.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.88
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About REVB

    Does REVB pay dividends?

    Revelation Biosciences Inc (REVB) does not currently pay a regular dividend.

    What is REVB's market cap?

    Revelation Biosciences Inc (REVB) has a market capitalization of $2.87M with a current stock price of $0.76.

    Related stocks

    Sector: Healthcare

    All stocks starting with R

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In